DOI: 10.2459/JCM.0000000000000516
,
,
PMID: 28306694
Issn Print: 1558-2027
Publication Date: 2017/06/01
Real-world use of ticagrelor and prasugrel in patients with NSTEMI undergoing percutaneous coronary intervention
Vincenzo Sucato; Egle Corrado; Carmelo Castellana; Michele Carella; Simona Raso; Giuseppe Coppola; Giuseppe Andolina; Giuseppina Novo; Salvatore Evola; Salvatore Novo
+ Author Information
Author Information: Division of Cardiology
Excerpt
Dual antiplatelet therapy is mandatory for all the patients with acute coronary syndrome, who underwent percutaneous coronary intervention (PCI).1 Prasugrel and ticagrelor, new inhibitors of the platelet adenosine diphosphate receptor P2Y12, should be preferred to clopidogrel.2,3 The next study sought to describe the safety and efficacy profile of both prasugrel and ticagrelor in patients with Non-ST-segment elevation myocardial infarction (NSTEMI), who were admitted to coronary ICU and underwent primary PCI.
Facebook
Twitter
LinkedIn
Email
